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Abstract For activation of kidney membrane phospholipase D
(PLD), cytosol is absolutely needed in addition to GTP-?-S. The 
active component of cytosol consists of three protein factors: 
ADP-ribosylation factor, RhoA, and a soluble 36-kDa protein. 
Any combination of these two factors synergistically activates 
PLD to some extent, but the presence of the three factors causes 
tall activation. The 36-kDa protein is stable at 60°C but 
inactivated at 80°C for 10 min. Tissue distribution of the 36-kDa 
protein roughly coincides with that of PLD, suggesting 
physiological relevance of the protein in the regulation of PLD. 
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1. Introduction 
Phospholipase D (PLD) catalyzes the hydrolysis of phos- 
phatidylcholine (PtdCho) in response to a wide variety of 
(~ternal signals (for review, see [1,2]). The mechanism of 
Iris enzyme activation has attracted considerable attention 
because the reaction may generate several lipid messengers 
~r mediators for cell signalling (for review, see [3,4]). Exten- 
ve studies with cell-free systems have shown the existence of 
i t  least two types of PLD in mammalian tissues: one is de- 
l 'endent on oleic acid [5-7] and the other is activated by small 
(;TP-binding regulatory proteins (G-proteins) such as ADP- 
1 bosylation factor (ARF) [8,9], RhoA [10,11], or Ral [12]. 
More recently, an additional protein factor has been reported 
1 aat is needed for guanosine 5'-O-(3-thiotriphosphate) 
43TP-~t-S)-dependent PLD activity. PLD obtained from 
lematopoietic ell lines is shown to be activated by a 50- 
~Da soluble protein and either ARF  [13,14] or RhoA [15]. 
];rain PLD is also activated by a cytosolic factor in a syner- 
r istic manner with ARF [16], and this factor has recently been 
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shown to be indistinguishable from protein kinase C (PKC) 
[17]. 
An earlier report from this laboratory has described that 
under normal conditions membrane-bound PLD is in a latent 
form, but exhibits a high activity in the presence of ammo- 
nium sulfate and cytosol [18]. Using this enzyme assay, the 
kidney and spleen are shown to contain highest G-protein- 
sensitive PLD activity. It has been also shown that the par- 
tially purified kidney PLD utilizes PtdCho as a preferential 
substrate, and requires nearly absolutely phosphatidylethanol- 
amine (PtdEtn) as a co-substrate [19]. The present study will 
show that the active component in the cytosol consists of 
ARF, RhoA, and an additional soluble 36-kDa protein, and 
that all of the three cytosolic proteins are needed to exhibit 
full PLD activation. Kinetics of the PLD activation by these 
factors and some properties of the 36-kDa protein will be 
described herein. 
2. Materials and methods 
2.1. Materials 
L-a-Dipalmitoyl[palmitoyl- 1-14 C]phosphatidylcholine ([a4C]PtdCho, 
115 mCi/mmol) and [3~S]GTP-y-S (1100 Ci/mmol) were purchased 
from DuPont-New England Nuclear. Phosphatidylethanol 
(PtdEtOH), a standard for TLC, was from Avanti Polar-Lipid, Inc. 
Plasmalogen-rich PtdEtn (60% plasmalogen) was from Serdary Re- 
search Laboratories (Englewood Cliffs, NJ). GTP-y-S was from Boeh- 
ringer-Mannheim. Glass-backed silica gel 60 was purchased from 
Merck. Monoclonal antibody against RhoA was purchased from San- 
ta Cruz Biotechnology (California). Isoprenylated RhoA and non-iso- 
prenylated RhoA fused to glutathione S-transferase expressed in and 
purified from Sf9 cell and Escheriehia coli, respectively, were kindly 
donated from Dr. K, Kaibuchi (Nara Institute of Science and Tech- 
nology). Polyclonal antibody, CK3 raised against a synthetic peptide 
(FARKGALRQKNVHEVKN) around the N-terminal portion of the 
~x-subspeeies of PKC was kindly donated from Dr. N. Saito (Biosignal 
Research Center, Kobe University). Purified conventional PKC was 
kindly donated from Dr. U. Kikkawa (Biosignal Research Center, 
Kobe University). 
2.2. Preparation of crude cytosol 
Proteins of the soluble fraction of rat kidney were precipitated with 
ammonium sulfate (30-70%), dissolved, dialyzed, and chromato- 
graphed on a Superdex 200 column as described earlier [18]. 
2,3. Preparation of PLD 
PLD was solubilized from the bovine kidney particulate fraction, 
and precipitated with MgC12 as described previously [19]. The fraction 
(70 mg protein) that contained PLD was applied to a hydroxyapatite 
column (Pharmacia) (2.4 × 4 cm; 18 ml) which had been equilibrated 
with buffer B [19]. After washing the column with 100 ml of buffer B, 
PLD was eluted with a 200-ml inear concentration gradient (0~).6 M) 
of potassium phosphate in buffer B at a flow rate of 1 ml/rnin. Frac- 
tions (5 ml each) were collected. The fractions containing PLD (po- 
tassium phosphate concentration at 0.25~0.4 M) were pooled and 
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concentrated to a minimum volume with an Amicon ultrafiltration 
cell equipped with PM-30 membrane, and dialyzed overnight against 
500 ml of buffer B. The dialyzed sample was clarified by centrifuga- 
tion for 30 min at 100000Xg, and applied to a TSK heparin 5PW 
(Toyo Soda (Tokyo); 0.6×4 cm) equipped with buffer B. After wash- 
ing with 10 ml of buffer B, the enzyme was eluted with a 20-ml linear 
concentration gradient (0-1.5 M) of NaC1 in buffer B at a flow rate of 
0.5 ml/min. Fractions (1 ml each) were collected. The fractions con- 
taining PLD (NaC1 concentration at 0.8-1.2 M) were pooled and 
concentrated to a protein concentration f 0.5 mg/ml by ultrafiltration 
as above, and stored at -80°C. The PLD preparation at this stage 
was purified about 1000-fold from particulate fractions. This prepara- 
tion was free of ARF, RhoA, and the 36-kDa protein (see below). The 
formation of PtdEtOH was linear with the enzyme protein up to 50 ng 
per tube, and the reaction proceeded linearly with incubation time up 
to 60 min. This purification made PLD more sensitive to the cytosol 
factors for its activation than that previously reported [18]. 
2.4. Purification of ARF 
ARF was purified from the bovine brain as described [20]. The final 
preparation of ARF after gel filtration (Superdex 75, Pharmacia) was 
about 87% pure by silver stain. This preparation was free of RhoA 
and the 36-kDa protein factor described below, as judged by immu- 
noblot analysis using a monoclonal antibody against RhoA and the 
factor activity (see below) to stimulate PLD with RhoA, respectively. 
2.5. PLD assay 
PLD activity was determined by measuring the formation of 
[14C]PtdEtOH from [14C]PtdCho in the presence of ethanol as des- 
cribed [18]. The reaction mixture (100 ~tl) contained 25 ng of PLD (see 
above), 6 nmol of [14C]PtdCho (13750 dpm/nmol), 7 nmol of plas- 
malogen-rich PtdEtn, 34.2 ~tmol of ethanol, 160 I.tmol of ammonium 
sulfate, 10 nmol of GTP-y-S, and 2 ~tmol of HEPES-NaOH at pH 7.4. 
Where indicated, additional factors (see below) were added to the 
assay mixture. 
2.6. Other procedures 
Protein was determined by the method of Bradford [21]. 
3. Results 
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Table 2 
Reconstitution of PLD activity with the 36-kDa protein, ARF, and 
RhoA 
Addition PtdEtOH produced (dpm × 10 -2) 
-GTP-y-S +GTP-y-S 
None 0.29 + 0.06 0.23 + 0.06 
36-kDa protein 0.40 + 0.10 0.22 + 0.05 
ARF 0.35 + 0.09 3.95 + 0.60 
RhoA 0.15 + 0.05 0.76 + 0.20 
36-kDa protein+ARF 0.36 + 0.11 18.00 + 2.30 
36-kDa protein+RhoA 0.29 + 0.09 1.60 + 0.24 
ARF+RhoA 0.23 + 0.15 9.01 + 0.98 
36-kDa protein+ARF+RhoA 0.30 + 0.11 36.20 + 4.03 
Crude cytosol from rat kidney was heated for 10 min at 60°C. Dena- 
tured proteins were removed by centrifugation for 10 min at 
10000×g, and the supernatant was used as a source of the 36-kDa 
protein. PLD was measured with 25 ng of enzyme in the presence or 
absence of 5/.tg of the 36-kDa protein, 470 nM ARF, 60 nM recom- 
binant RhoA, and 100 ~tM GTP-y-S as indicated. Results are the 
means + S.E.M. of duplicate determinations from three separate x- 
periments. 
activation of PLD (Fig. 1). The combined addition of the 
three components, ARF,  RhoA,  and the 36-kDa protein, fully 
restored the PLD activity that was observed in the presence of 
crude cytosol (Tables 1 and 2). 
3.2. Properties of the 36-kDa protein 
The 36-kDa protein retained its stimulatory activity after 
being heated for 10 min at 60°C, but was inactivated com- 
pletely upon treatment for 10 min at 80°C. Small G-proteins 
were inactivated by the heat treatment for 10 min at 60°C. 
3.1. Reconstitution of PLD activity 
Purified bovine kidney PLD per se was practically inactive, 
and required almost absolutely both crude cytosol and 
GTP-7-S to exhibit enzymatic activity (Table 1). When the 
cytosol was replaced by ARF,  the enzyme showed some ac- 
tivity, but did not exhibit full activation unless cytosol was 
added. Kinetic analysis indicated that this cytosolic factor 
consisted of at least two G-proteins and an additional 36- 
kDa protein (see below). Recombinant  isoprenylated RhoA 
could substitute for one of the two G-proteins, although 
RhoA alone was inert to support the enzymatic activity 
both in the presence and in the absence of the 36-kDa protein 
(Table 2). Non-isoprenylated RhoA was without effect. With 
a saturated amount  (5 ~tg) of the 36-kDa protein, which was 
inactive by itself, RhoA enhanced further the ARF-dependent  
Table 1 
Reconstitution of PLD activity with crude cytosol 
Addition PtdEtOH produced (dpm× 10 -2) 
-GTP-y-S +GTP-y-S 
None 0.38 ± 0.15 0.22 + 0.06 
Crude cytosol 0.28 + 0.10 34.38 _+ 5.11 
PLD activity was measured with 25 ng of enzyme in the presence or 
absence of 100 lxg of crude cytosol from rat kidney and 100 ].tM 
GTP-y-S as indicated. The reaction was carried out for 20 min at 
37°C, and the radioactive PtdEtOH produced was determined. Results 
are the means + S.E.M. of duplicate determinations from three sepa- 
rate experiments. 
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Fig. 1. Reconstitution of GTP-y-S-dependent PLD activity with 
ARF, RhoA, and the 36-kDa protein. The 36-kDa protein was pre- 
pared as in the legend to Table 2. PLD activity was measured with 
25 ng of enzyme in the presence or absence of 470 nM purified 
ARF, 60 nM recombinant RhoA, and various concentrations of the 
36-kDa protein, e-e, with ARF plus RhoA; O-O, with ARF; m-D, 
with RhoA; a -a ,  without any G-protein. 
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This heated fraction was centrifuged for 10 min at 10000xg 
to remove denatured proteins, and the supernatant was sub- 
jected to a Superose 12 gel filtration column. The activity to 
support PLD activation was eluted as a single peak with an 
approximate molecular mass of 36 kDa (Fig. 2). Trypsin 
treatment completely inactivated the factor• The results indi- 
cate that the 36-kDa factor is a protein. The amount of the 
3~,-kDa protein varied from tissue to tissue with the following 
o~der: kidney > liver > spleen > brain=lung (Fig. 3). The dis- 
t~ Lbution pattern of the factor roughly coincided with that of 
P 2D. The heat-stable factor did not affect [aSS]GTP-~t-S bind- 
il~g to ARF. 
4 Discussion 
Subsequent to the reports by Brown et al. [8] and Cockcroft 
e: al. [9], several papers have appeared escribing the involve- 
n ent of small G-proteins in PLD activation. Brain mem- 
b'ane-bound PLD has been shown to be activated by the 
synergistic action of ARF and RhoA [16,22]. Liver mem- 
b'ane-bound PLD has also been shown to be activated by 
RhoA [11]. In HL-60 cells, cytosolic PLD is activated by 
A RF, whereas membrane-bound PLD is activated by ARF 
aad RhoA synergistically [23]. The stimulatory mechanism 
c 'PLD by small G-proteins is at present unclear, and it 
r,.mains uncertain whether the distinct sensitivity of the en- 
z rme to several G-proteins reflects enzyme heterogeneity or
i,, apurity of the enzyme preparations employed. The present 
r ,sults suggest that one type of PLD in kidney is synergistic- 
a ly activated by ARF, RhoA, and the 36-kDa protein. 
The 36-kDa protein may differ from the 50-kDa protein in 
h ~matopoietic cell lines [13-15] in molecular size. The 36-kDa 
F-otein showed no immunological cross-reactivity with an 
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! ig. 2. Superose 12 column chromatography of the 36-kDa protein. 
7 he 36-kDa protein containing fraction (1 mg protein) prepared as 
i~ the legend to Table 2 was applied to a Superose 12 column 
x~hich ad been equilibrated with buffer A [18], and eluted with the 
s,tme buffer at a flow rate 0.5 ml/min using an FPLC system (Phar- 
macia). Fractions (1 ml each) were collected. Each fraction (20 p]) 
x~ as assayed for PLD activation with 25 ng of enzyme, 470 nM pur- 
itied ARF, and 100 ~tM GTP-7-S under the conditions specified. Ar- 
rows indicate the elution positions of blue dextran (2000 K), oval- 
bumin (43 K), and chymotrypsinogen A (25 K) which were run in 
parallel experiments. 
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Fig. 3. Tissue distribution of the 36-kDa protein and PLD. Super- 
natant and particulate fractions were prepared from various rat tis- 
sues [18]. The soluble cytosols (10 mg/ml) were heated for 10 min at 
60°C and centrifuged to remove the denatured proteins. PLD acti- 
vation (hatched bar) by each cytosol (20 lal) was measured with 25 
ng of partially purified enzyme, 470 nM purified ARF, and 100 laM 
GTP-7-S under the conditions pecified. Data are expressed as fold 
increase over control value obtained in the absence of the 36-kDa 
protein. PLD activity (open bar) of each particulate fraction (50 lag 
protein) was measured with 100 lag of crude cytosol from rat kidney 
and 100 laM GTP-y-S as in [18]. Results are the means+S.E.M, of 
duplicate determinations from three separate experiments. 
antibody raised against a synthetic peptide around the 
N-terminal portion of the c~-subspecies of PKC, suggesting 
that the 36-kDa protein is not derived from PKC. Structural 
and kinetic analysis of the 36-kDa protein remains to be ex- 
plored. 
The present studies with preparations of several protein 
components free of one another show that the kidney mem- 
brane PLD requires imultaneously at least three soluble pro- 
teins, ARF, RhoA, and the 36-kDa protein, to exhibit full 
enzymatic activity. ARF and RhoA have been shown to exist 
in kidney [24,25]. An earlier paper [19] has shown that PtdEtn 
is essential, perhaps as a co-substrate, for kidney PLD. In 
addition, it has been confirmed that tyrosine kinase and pro- 
tein kinase C take part in the regulation of the enzyme activity 
[26]. Reconstitution analysis of these regulatory components 
described above with purified enzyme may be essential to 
clarify the mechanism of receptor-mediated activation of 
mammalian PLD. 
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